Müller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, Tusch G, Lautz H U, Böker K, Stangel W
Abteilung für Gastroenterologie und Hepatologie, Medizinische Hochschule Hannover, Federal Republic of Germany.
J Hepatol. 1991 Jul;13(1):90-6. doi: 10.1016/0168-8278(91)90869-d.
Liver transplantation in HBs-antigen (HBsAg) positive allograft recipients is associated with a high risk of HBV recurrence some time after surgery. So far, results of measures to prevent recurrent HBV-infection by means of treatment with interferon, hepatitis B vaccination and short-term passive immunization with hepatitis B immunoglobulin (HBIg) or monoclonal antibody to HBsAg (anti-HBs) have been disappointing. In the present study the results of long-term, anti-HBs monitored passive immunization with HBIg is reported. In 23 HBsAg-positive liver transplant recipients an anti-HBs level of greater than or equal to 100 IU/l was maintained for 6 or 12 months, respectively. The rate of recurrent infection was found to be less than 20% under HBIg substitution, whereas 11 graft recipients with no or only short-term HBIg prophylaxis were reinfected by month 15 after transplantation. HBV recurrence was associated with chronic liver disease and recurrent cirrhosis in the allograft.
乙肝表面抗原（HBsAg）阳性的同种异体移植受者进行肝移植后，术后一段时间内乙肝病毒（HBV）复发风险很高。到目前为止，通过干扰素治疗、乙肝疫苗接种以及乙肝免疫球蛋白（HBIg）或乙肝表面抗原单克隆抗体（抗-HBs）短期被动免疫来预防HBV复发感染的措施效果一直不尽人意。在本研究中，报告了长期、监测抗-HBs水平的HBIg被动免疫的结果。在23例HBsAg阳性肝移植受者中，抗-HBs水平分别维持在大于或等于100 IU/l达6个月或12个月。发现HBIg替代治疗下复发感染率低于20%，而11例未进行或仅进行短期HBIg预防的移植受者在移植后15个月时再次感染。HBV复发与同种异体移植中的慢性肝病和复发性肝硬化有关。
Zotero 插件